Zelluna Immunotherapy
Blood & Organ Banks · Norway · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Ullernchausséen 64, Oslo, Oslo, 0379, No...Phone Number
+46 859478830Website
www.zelluna.comRevenue
$6.3 MillionIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
2
2
2
2
About Zelluna Immunotherapy
Zelluna is a pioneering company developing novel cell therapies specifically targeting solid cancers to improve treatment outcomes for cancer patients. The company focuses on its proprietary TCR-NK cell therapy platform, which aims to overcome existing challenges in solid cancer treatment. Zelluna's experienced team and strong intellectual property position enable it to pursue promising developments in the cell therapy field. Their mission is to transform cancer care by advancing innovative therapies that harness the immune system's capabilities.Explore more
Zelluna Immunotherapy Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zelluna Immunotherapy your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Zelluna Immunotherapy recently announced quarterly report
Product Launch: Get notified when Zelluna Immunotherapy launches new products
Funding: Get notified immidiatlly once Zelluna Immunotherapy has new funding data
Zelluna Immunotherapy, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Zelluna Immunotherapy has recently received funding, and reach out quickly before it becomes old news!
Check out if Zelluna Immunotherapy is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Zelluna Immunotherapy
Website visits: Recent activity has been detected on your website
Click to see if Zelluna Immunotherapy had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Zelluna Immunotherapy as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Zelluna Immunotherapy is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Zelluna Immunotherapy is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Zelluna Immunotherapy.
Zelluna Immunotherapy financials insights
Gather financial insights about Zelluna Immunotherapy, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$8.5M
Other Financing Round
$6M
Zelluna Immunotherapy Tech Stack
A closer look at the technologies used by Zelluna Immunotherapy
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Promotion
Executive Move
Executive Moves, Promotion
Promotion
Executive Move
Executive Moves, Promotion
Lateral Move
Executive Move
Executive Moves, Lateral Move
Promotion
Executive Move
Executive Moves, Promotion
Zelluna Immunotherapy News & Media
Zelluna ASA - Grant of Share Options
Oslo, 2 July 2026: On the basis of the authorization granted by the General Meeting on 23 April 2026 for the Board of Directors of Zelluna ASA (the “Company”, OSE ticker “ZLNA”) to issue shares to employees and board members under a long-term incentive program, the Board of Directors has resolved to grant 12,000 share options to two Board members in the Company.Zelluna ASA awarded NOK 16 million Research Council of Norway grant
Oslo, 29 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the Research Council of Norway has approved a grant of NOK 16 million to Zelluna under the Innovation Project for the Industrial Sector (IPN) scheme.Zelluna ASA: New share capital registered
Oslo, Norway, 29 June 2026: Reference is made to the stock exchange announcement published by Zelluna ASA (the “Company”) on 18 June 2026 regarding a successfully placed private placement (the “Private Placement”) and a retail offering (the “Retail Offering”) as described therein. Reference is also made to the resolution of the Board of Directors of the Company to issue 2,972,973 new shares in the Company in the Private Placement and 170,985 new shares in theZelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities
Oslo, 29 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that The Royal Marsden NHS Foundation Trust has been activated as the second clinical site in the ZIMA-101 Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate.
Read more news
Top Blood & Organ Banks Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Zelluna Immunotherapy
Sign Up For FreeTo access detailed company insights
Zelluna is a pioneering company developing novel cell therapies specifically targeting solid cancers to improve treatment outcomes for cancer patients. The company focuses on its proprietary TCR-NK cell therapy platform, which aims to overcome existing challenges in solid cancer treatment. Zelluna's experienced team and strong intellectual property... Read More
